Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $698K | $3.10M | $123K | $261K | $0.00 | — |
| Revenue growth | — | 343.9% | -96.0% | 111.0% | -100.0% | — |
| Operating income | -$2.82M | -$14.8M | -$18.1M | -$20.1M | -$28.6M | -$52.0M |
| Operating margin | -403.5% | -476.2% | -14686.2% | -7712.0% | — | — |
| Net income | -$2.85M | -$14.8M | -$18.1M | -$19.0M | -$27.5M | -$48.3M |
| Net margin | -407.7% | -476.9% | -14625.9% | -7304.7% | — | — |
| EPS (diluted) | -$0.35 | -$0.81 | -$4.28 | -$3.16 | -$1.16 | -$0.49 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$1.13M | -$14.3M | -$17.4M | -$18.1M | -$19.1M | -$27.8M |
| Capital expenditures | — | $0.00 | $243K | $14.2K | $0.00 | $13.4K |
| Free cash flow | — | -$14.3M | -$17.6M | -$18.1M | -$19.1M | -$27.8M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $14.0M | $40.8M | $7.19M | $9.20M | $97.5M | $179M |
| Total assets | $14.8M | $42.5M | $24.9M | $14.5M | $98.6M | $181M |
| Total liabilities | $5.00M | $4.05M | $3.90M | $3.53M | $3.73M | $8.30M |
| Long-term debt | — | $249K | — | $382K | — | — |
| Shareholders' equity | $9.78M | $38.4M | $21.0M | $11.0M | $94.9M | $173M |
| Retained earnings | $15.0M | -$29.8M | -$47.9M | -$66.9M | -$94.4M | -$143M |
| Shares (wtd avg diluted) | 10.1M | 18.2M | 4.22M | 6.03M | 23.7M | 98.3M |
Every figure is extracted from Inhibikase Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.